-
Ritalin-Cancer Link: Researchers Emphasize Their Finding was Preliminary, Only
The FDA is Investigating the Possibility of a Ritalin-Cancer Association In late June 2005 it was widely reported that the FDA was examining a potential link between Ritalin and cancer. What did not get…
-
FDA Knew of Possible Viagra-Blindness Link as Early as January 2004
Senator Grassley's June 2005 Letter Criticizes FDA's Delay in Alerting Doctors and Patients In January 2004 an FDA safety officer told her FDA supervisors that doctors and patients should be warned of a possible…
-
June 2005 BMJ Editorial Calls for Fundamental Changes to Drug Regulation
Current Drug-safety Methods Used by Regulators are Out-dated The July 2, 2005 edition of BMJ, a British medical journal, contains a thoughtful editorial entitled "Drug safety and regulation: New powers and resources are needed".…
-
Vioxx Recall Showed Inadequacy of FDA’s Current Drug-safety Monitoring Systems
Expert: Post-marketing Studies Must be Strengthened to Find Meaning of "Signals" Early On On June 29, 2005 Dr. David Wofsy, a rheumatologist associated with the University of California at San Francisco, told an audience…
-
Novantrone: FDA MedWatch Alert Regarding Heart Damage Risks
April 2005 "Dear Doctor" Letter Also Addressed an Increased Risk of AML In late May 2005 the FDA warned patients of the risk of heart damage from Serono’s multiple sclerosis drug Novantrone. In a…
-
Pfizer Maintains There is No NAION / Blindness Risk from Viagra
Bayer Has Not Decided Whether to Add NAION Warning for Levitra On June 27, 2005 Pfizer Inc. issued a press release asserting that there is no evidence of any increased risk of developing non-arteritic…
